3347:HKEXHangzhou Tigermed Consulting Co., Ltd. Class H Analysis

Hangzhou Tigermed is trading at HK$32.04, which sits above its DCF‑derived fair value of roughly HK$29.9 and exceeds the industry‑average P/E of 27.6, indicating an overvalued price level. The stock is deep in the bearish zone of its 20‑day (≈37.7) and 50‑day (≈40.2) SMAs, with the 14‑day RSI at 24.9 and a bearish MACD histogram, suggesting continued downside pressure toward the identified support around HK$31.72. However, the RSI also flags an oversold condition, and volume is trending higher, which could provide a short‑term bounce.
Fundamentally, Tigermed posted 15.2% revenue growth, a solid operating cash flow of over HK$1.2 bn and a modest dividend yield of 1.01% supported by a payout ratio near 33%, pointing to dividend sustainability. Analysts are bullish, with a consensus “buy” and median price target of HK$56.4, yet the company carries a high debt‑to‑equity ratio of 7.0 and operates in a sector subject to stringent Chinese regulatory scrutiny, adding to medium‑to‑high risk considerations.